MétaCan
Menu
← Back to cohort
Record W4415355988 · doi:10.1158/1078-0432.ccr-24-3785

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma

2025· article· en· W4415355988 on OpenAlexaff
Jennifer Wiggins, Qiao Zhang, Yian Zhang, Fatemeh Vand-Rajabpour, Douglas Hanniford, Linchen He, Yuting Lu, Jessica Kenney, Keimya Sadeghi, Diana Argibay, Irene Orlow, Klaus J. Busam, Cecilia Lezcano, Tim K. Lee, Li Luo, Ivan Gorlov, Christopher I. Amos, Marc S. Ernstoff, Venkatraman Seshan, Anne Ε. Cust, James S. Wilmott, Richard A. Scolyer, Graham J. Mann, Allison Reiner, Caroline E. Kostrzewa, Eduardo Nagore, Pauline Funchain, Jennifer S. Ko, Sharon N. Edmiston, Kathleen Conway, Paul B. Googe, David W. Ollila, Jeffrey E. Lee, Judy R. Rees, Cheryl L. Thompson, Meg R. Gerstenblith, Marcus Bosenberg, Bonnie E. Gould Rothberg, Iman Osman, Yvonne M. Saenger, Adam Z. Reynolds, Tawny W. Boyce, Sheri L. Holmen, Shaofeng Yan, Elise K. Brunsgaard, Paul N. Bogner, Pei Fen Kuan, Nancy E. Thomas, Colin B. Begg, Ronglai Shen, Marianne Berwick, Yongzhao Shao, David Polsky, Eva Hernando

Bibliographic record

VenueClinical Cancer Research · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMicroRNA in disease regulation
Canadian institutionsCanadian Centre for Applied Research in Cancer Control
FundersNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institute of Environmental Health SciencesNational Institute of General Medical SciencesNational Cancer Institute
KeywordsMelanomaStage (stratigraphy)microRNAAdjuvantCancerSelection (genetic algorithm)

Abstract

fetched live from OpenAlex

PURPOSE: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. EXPERIMENTAL DESIGN: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. RESULTS: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a "clinical factors-only" model to 0.81 for a "clinical plus miRNA" model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03-0.19). The improvement was more modest for patients in stage III who were included in the analysis. CONCLUSIONS: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.424
Teacher spread0.388 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer Research→Same topicMicroRNA in disease regulation→French-language works237,207→